Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
16 07 2020
Historique:
received: 18 07 2019
accepted: 27 03 2020
pubmed: 23 4 2020
medline: 27 2 2021
entrez: 23 4 2020
Statut: ppublish

Résumé

B-cell acute lymphoblastic leukemia (ALL; B-ALL) is the most common pediatric cancer, and high hyperdiploidy (HyperD) identifies the most common subtype of pediatric B-ALL. Despite HyperD being an initiating oncogenic event affiliated with childhood B-ALL, the mitotic and chromosomal defects associated with HyperD B-ALL (HyperD-ALL) remain poorly characterized. Here, we have used 54 primary pediatric B-ALL samples to characterize the cellular-molecular mechanisms underlying the mitotic/chromosome defects predicated to be early pathogenic contributors in HyperD-ALL. We report that HyperD-ALL blasts are low proliferative and show a delay in early mitosis at prometaphase, associated with chromosome-alignment defects at the metaphase plate leading to robust chromosome-segregation defects and nonmodal karyotypes. Mechanistically, biochemical, functional, and mass-spectrometry assays revealed that condensin complex is impaired in HyperD-ALL cells, leading to chromosome hypocondensation, loss of centromere stiffness, and mislocalization of the chromosome passenger complex proteins Aurora B kinase (AURKB) and Survivin in early mitosis. HyperD-ALL cells show chromatid cohesion defects and an impaired spindle assembly checkpoint (SAC), thus undergoing mitotic slippage due to defective AURKB and impaired SAC activity, downstream of condensin complex defects. Chromosome structure/condensation defects and hyperdiploidy were reproduced in healthy CD34+ stem/progenitor cells upon inhibition of AURKB and/or SAC. Collectively, hyperdiploid B-ALL is associated with a defective condensin complex, AURKB, and SAC.

Identifiants

pubmed: 32321174
pii: S0006-4971(20)61882-1
doi: 10.1182/blood.2019002538
pmc: PMC7413752
doi:

Substances chimiques

DNA-Binding Proteins 0
Multiprotein Complexes 0
Neoplasm Proteins 0
condensin complexes 0
AURKB protein, human EC 2.7.11.1
Aurora Kinase B EC 2.7.11.1
Adenosine Triphosphatases EC 3.6.1.-

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

313-327

Subventions

Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/P002412/1
Pays : United Kingdom

Informations de copyright

© 2020 by The American Society of Hematology.

Références

Nat Rev Mol Cell Biol. 2015 Aug;16(8):473-85
pubmed: 26204159
Blood. 2012 Aug 9;120(6):1165-74
pubmed: 22730540
Leukemia. 1993 Jan;7(1):10-9
pubmed: 8418369
Nat Genet. 2015 Jun;47(6):672-6
pubmed: 25961940
Curr Opin Cell Biol. 2011 Feb;23(1):102-8
pubmed: 20702077
J Cell Biol. 2013 Oct 14;203(1):87-100
pubmed: 24100295
Nat Commun. 2019 Apr 3;10(1):1519
pubmed: 30944321
Cancer Genet Cytogenet. 2010 Dec;203(2):209-14
pubmed: 21156235
Science. 1995 Sep 8;269(5229):1429-31
pubmed: 7660126
Biology (Basel). 2017 Feb 08;6(1):
pubmed: 28208750
Lancet Oncol. 2010 May;11(5):429-38
pubmed: 20409752
Br J Haematol. 2003 Mar;120(5):846-9
pubmed: 12614220
PLoS One. 2009 Aug 28;4(8):e6831
pubmed: 19714251
Cell Cycle. 2010 Aug 15;9(16):3243-55
pubmed: 20703077
Nat Rev Cancer. 2018 Aug;18(8):471-484
pubmed: 29784935
Genes Dev. 2002 Feb 15;16(4):399-414
pubmed: 11850403
Genes Chromosomes Cancer. 2007 Jul;46(7):684-93
pubmed: 17431878
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10484-9
pubmed: 20483991
Nat Commun. 2017 May 31;8:15542
pubmed: 28561035
Dev Cell. 2003 Aug;5(2):323-36
pubmed: 12919682
Oncotarget. 2014 Nov 30;5(22):11501-12
pubmed: 25415224
Lancet. 1997 Feb 1;349(9048):344-9
pubmed: 9024390
Leukemia. 2003 Nov;17(11):2202-6
pubmed: 12931229
Chromosoma. 1985;92(4):290-6
pubmed: 2994966
Dev Cell. 2014 Sep 8;30(5):496-508
pubmed: 25203206
Chromosoma. 2018 Jun;127(2):215-227
pubmed: 29411093
Eur J Cell Biol. 2012 May;91(5):413-9
pubmed: 22365812
Leukemia. 2014 Apr;28(4):977-9
pubmed: 24186003
Haematologica. 2013 Sep;98(9):1424-32
pubmed: 23645689
Br J Haematol. 2011 Jul;154(2):275-7
pubmed: 21518330
Nat Rev Genet. 2012 Jan 24;13(3):189-203
pubmed: 22269907
Genes Chromosomes Cancer. 2009 Aug;48(8):637-60
pubmed: 19415723
J Biol Chem. 2019 Feb 1;294(5):1437-1450
pubmed: 30498087
Ann Hematol. 2012 May;91(5):793-796
pubmed: 21947032
Cold Spring Harb Symp Quant Biol. 2010;75:445-51
pubmed: 21289044
Genes Dev. 2018 Dec 1;32(23-24):1485-1498
pubmed: 30463904
Leukemia. 2015 Aug;29(8):1656-67
pubmed: 25917266
Leukemia. 2015 Jan;29(1):58-65
pubmed: 24897505
Nat Rev Mol Cell Biol. 2012 Dec;13(12):789-803
pubmed: 23175282
Bioessays. 1995 Sep;17(9):759-66
pubmed: 8763828
Br J Haematol. 2005 May;129(4):520-30
pubmed: 15877734
Leukemia. 2016 Aug;30(8):1691-700
pubmed: 27109511
Genes Chromosomes Cancer. 2004 May;40(1):38-43
pubmed: 15034866
Blood. 2003 Oct 15;102(8):2756-62
pubmed: 12829593
Nature. 2001 Mar 1;410(6824):120-4
pubmed: 11242054
Trends Genet. 2019 Apr;35(4):279-291
pubmed: 30745166
Nat Cell Biol. 2010 Dec;12(12):1186-93
pubmed: 21102442
Exp Cell Res. 2004 May 15;296(1):35-42
pubmed: 15120991
J Cell Biol. 2010 Mar 8;188(5):665-79
pubmed: 20212316
Oncogene. 2010 Jun 3;29(22):3307-12
pubmed: 20190817
Curr Biol. 1997 Nov 1;7(11):901-4
pubmed: 9382805
Pediatr Blood Cancer. 2014 Dec;61(12):2208-14
pubmed: 25174722
Chromosome Res. 2016 Dec;24(4):495-509
pubmed: 27924426
Elife. 2018 Aug 06;7:
pubmed: 30080136
Leukemia. 2018 Mar;32(3):633-644
pubmed: 28943635
Blood. 2013 Mar 28;121(13):2374-6
pubmed: 23538228
Genes Dev. 2016 Oct 1;30(19):2173-2186
pubmed: 27737961
J Cell Sci. 2012 Mar 15;125(Pt 6):1591-604
pubmed: 22344259
Blood. 1992 May 1;79(9):2370-7
pubmed: 1373973
Trends Biochem Sci. 2016 Feb;41(2):160-174
pubmed: 26705896
Genes Dev. 1995 Jan 15;9(2):218-33
pubmed: 7851795
Nat Commun. 2015 Jul 06;6:7668
pubmed: 26144554
Curr Biol. 1997 Nov 1;7(11):897-900
pubmed: 9382804

Auteurs

Oscar Molina (O)

Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.

Meritxell Vinyoles (M)

Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.

Isabel Granada (I)

Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Hematology Laboratory, Germans Trias i Pujol University Hospital-Catalan Institute of Oncology, Badalona, Spain.

Heleia Roca-Ho (H)

Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.

Francisco Gutierrez-Agüera (F)

Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.

Luis Valledor (L)

Department of Physical and Analytical Chemistry, University of Oviedo, Asturias, Spain.

Carlos M López-López (CM)

Department of Physical and Analytical Chemistry, University of Oviedo, Asturias, Spain.

Pablo Rodríguez-González (P)

Department of Physical and Analytical Chemistry, University of Oviedo, Asturias, Spain.

Juan L Trincado (JL)

Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.

Sofía T Menéndez (ST)

Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias, Oviedo, Spain.
CIBER-ONC, ISCIII, Madrid, Spain.

Deepali Pal (D)

Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
Department of Applied Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom.

Paola Ballerini (P)

Pediatric Hematology, A. Trousseau Hospital, Paris, France.

Monique L den Boer (ML)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Isabel Plensa (I)

Hematology Laboratory, Institut Recerca Hospital Sant Joan de Déu, Barcelona, Spain.

M Mar Perez-Iribarne (M)

Hematology Laboratory, Institut Recerca Hospital Sant Joan de Déu, Barcelona, Spain.

Sandra Rodríguez-Perales (S)

Molecular Cytogenetics Group, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain.

María José Calasanz (MJ)

CIMA Laboratory Diagnostics, Universidad de Navarra, Pamplona, Spain.

Manuel Ramírez-Orellana (M)

Hematology Diagnostic Laboratory, Hospital Niño Jesús, Madrid, Spain.

René Rodríguez (R)

Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias, Oviedo, Spain.
CIBER-ONC, ISCIII, Madrid, Spain.

Mireia Camós (M)

Hematology Laboratory, Institut Recerca Hospital Sant Joan de Déu, Barcelona, Spain.
Leukemia and Other Pediatric Hemopathies, Developmental Tumors Biology Group, Institut de Recerca Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Barcelona, Spain.

Maria Calvo (M)

Scientific and Technological Centers, Universitat de Barcelona (CCiTUB) Campus Clínic, Barcelona, Spain; and.

Clara Bueno (C)

Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.

Pablo Menéndez (P)

Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH